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Background: The catecholaminergic and serotonergic neurotransmitter systems are implicated in the
pathophysiology of attention-deficit/hyperactivity disorder (ADHD). The amino acid tyrosine is the precursor for
synthesis of the catecholamines dopamine and norepinephrine, while tryptophan is the precursor of serotonin.
A disturbed transport of tyrosine, as well as other amino acids, has been found in a number of other psychiatric
disorders, such as schizophrenia, bipolar disorder and autism, when using the fibroblast cell model. Hence, the aim
of this study was to explore whether children with ADHD may have disturbed amino acid transport.
Methods: Fibroblast cells were cultured from skin biopsies obtained from 14 boys diagnosed with ADHD and from
13 matching boys without a diagnosis of a developmental disorder. Transport of the amino acids tyrosine,
tryptophan and alanine across the cell membrane was measured by the cluster tray method. The kinetic
parameters, maximal transport capacity (Vmax) and affinity constant (Km) were determined. Any difference between
the two groups was analyzed by Student’s unpaired t-test or the Mann Whitney U test.
Results: The ADHD group had significantly decreased Vmax (p = 0.039) and Km (increased affinity) (p = 0.010) of
tryptophan transport in comparison to controls. They also had a significantly higher Vmaxof alanine transport (p =
0.031), but the Km of alanine transport did not differ significantly. There were no significant differences in any of
the kinetic parameters regarding tyrosine transport in fibroblasts for the ADHD group.
Conclusions: Tryptophan uses the same transport systems in both fibroblasts and at the blood brain barrier (BBB).
Hence, a decreased transport capacity of tryptophan implies that less tryptophan is being transported across the BBB
in the ADHD group. This could lead to deficient serotonin access in the brain that might cause disturbances in both
the serotonergic and the catecholaminergic neurotransmitter systems, since these systems are highly interconnected.
The physiological importance of an elevated transport capacity of alanine to the brain is not known to date.
Background
Attention-deficit/hyperactivity disorder (ADHD) is a
neurodevelopmental disorder with a prevalence in chil-
dren of about 5-7% worldwide [1,2]. It is clinically char-
acterized by a persistent pattern of inattention and/or
hyperactivity-impulsivity that affect cognitive, beha-
vioural, emotional and social functioning and symptoms
may also persist into adulthood [1,3,4].
As for many other neurodevelopmental disorders no
single etiology of ADHD has been provided, but a num-
ber of underlying theories exist. The disorder is highly
heritable, based on family, twin and adoption studies [5],
but the genetic architecture of ADHD is suspected to be
complex. However, a number of candidate genes have
been identified and among these are several genes asso-
ciated with the catecholaminergic system [6]. Also, a
recent study shows that children with ADHD have an
increased rate of large copy number variants (CNVs)
especially at chromosome 16 [7], which further support
ADHD as a genetic disorder.
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ities of brain structure and function in ADHD and in
particular, a dysfunction of the fronto-subcortical path-
ways in the brain has been implicated [8]. These path-
ways control attention and motor behaviour, and it is
known that the catecholamines; dopamine and norepi-
nephrine, are vital for their function [8]. Moreover, sti-
mulant agents, such as methylphenidate, amphetamine
and atomoxetine, which currently are the most common
drugs used for treatment of ADHD, act primarily on the
catecholaminergic system. Therefore, the neurotransmit-
ters dopamine and norepinephrine have been implicated
in the pathophysiology of ADHD. However, an involve-
ment of serotonin and the serotonergic system in the
pathophysiology of ADHD have also regained the
researchers’ interest during recent years, since there is an
interaction between the dopaminergic and serotonergic
neurotransmitter systems. It is suggested that serotonin
can modulate the activity of dopamine and an alteration
in the serotonergic neurotransmission can alter dopa-
mine-mediated behaviour [9,10]. Still, the relevance of
serotonin in ADHD needs to be further explored.
The rate of synthesis of the neurotransmitters dopamine,
norepinephrine and serotonin in the central nervous
system (CNS) is partly dependent on the brain’s availability
of precursor amino acids [11]. The amino acid tyrosine is
the precursor for the synthesis of dopamine and norepi-
nephrine, while tryptophan is the precursor for the synth-
esis of serotonin and both amino acids are essential for the
brain. Amino acids are polar molecules and are therefore
actively transported across cell membranes, like the
endothelial cells that constitute a part of the blood brain
barrier (BBB), by different amino acid transport systems
[12-14]. A competition between amino acids using the
same transporters exists [13,15]. A number of different
amino acid transport systems, with different amino acid
selectivity, have been identified to date, such as system L,
system A, and system ASC [12].
In order to study amino acid transport properties, in
various psychiatric disorders, fibroblast cells are being
used as a human experimental model. This model is
suggested to be relevant since fibroblasts have a similar
expression of amino acid transporters as human brain
microvascular endothelial cells (hBME) and express sev-
eral neuronal specific receptors and enzymes [15-18].
Recent studies have also shown that fibroblast cells can
be converted into functional neurons [19]. Moreover,
they are easily obtained from both patients and controls,
and in comparison to other cell types they can be
grown in larger amounts, are stable for many genera-
tions and are not affected by prior medication status of
the patient [16].
The transport of both tyrosine and tryptophan has
recently been characterized in fibroblast cells. Tyrosine
was found mainly to be transported by system L, with
LAT1 as the main transporter [15], in accordance with
the transport of tyrosine through human brain micro-
vascular endothelial cells [18,20,21]. Tyrosine is also, to
a less extent, transported through system A, by its iso-
form ATA2 [12]. System A is known to transport short-
chain amino acids, such as alanine, but in a study by
Vumma et al in 2008 [15] it was demonstrated that
approximately 50% of alanine was transported through
the LAT1 isoform of system L, which denotes a compe-
tition between alanine and tyrosine to get transported.
The transport of tryptophan in fibroblast cells is
mediated by multiple transporters that are active at dif-
ferent substrate concentrations [22]. However, at physio-
logical tryptophan plasma concentrations the transport
is mainly through the LAT1 isoform of system L [22].
When using the fibroblast cell model, previous findings
by our group [23-29] and others [30] have shown a dis-
turbed membrane transport of tyrosine in a number of
psychiatric disorders, such as schizophrenia, autism and
bipolar disorder, Moreover, in a previous study by our
group, we found that children with autism had an
increased transport capacity of alanine across cell mem-
branes [24]. An elevated transport of alanine across the
BBB might influence the transport of other amino acids
that are of vital importance for normal brain activity,
since amino acids using the same transporter compete
for transport [13,15].
The aim of this study was to investigate whether chil-
dren with ADHD have changes in the transport of tyrosine
and/or tryptophan, since these amino acids are the precur-
sors for the neurotransmitters implicated in the pathophy-
siology of ADHD. Moreover, as there is a competition
between tyrosine and alanine we studied the transport of
alanine in children with ADHD.
Materials and Methods
Children with ADHD
The study included fibroblast cell lines from 14 boys with
ADHD of the combined type (inattention combined with
hyperactivity and impulsivity), according to the DSM-IV
criteria [31]. They were between 6-12 years old (mean 10
years) at the time of the study. All were patients at the
Unit of Neurodevelopmental Disorders, Department of
Pediatrics, Skaraborg Hospital, Mariestad which is a pri-
mary pediatric referral center for pharmacological treat-
ment of children and adolescents with ADHD. The
patients had been diagnosed by an experienced team
within the unit with support from standardized ADHD-
rating scales used by clinicians, teachers and parents as
well as with a general pediatric and psychological/cogni-
tive work up. First grade relatives with ADHD or disrup-
tive disorder, in addition to an uneventful pregnancy and
perinatal period, were considered as an indication of
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asthma and still three others were overweight. Symptoms
for motor coordination disorder, oppositional defiant dis-
order, conduct disorder, intellectual disability and autism
spectrum disorder were checked for but not diagnosed at
the time for the study. Both intellectual disability and
autism spectrum disorder were exclusion criterias. All
children were pharmacologically treated, twelve with
methylphenidate and two with atomoxetine.
Comparison group
The comparison group consisted of fibroblast cell lines
from 13 boys matched for age and without a diagnosis of a
developmental disorder, between 7 and 13 years old (mean
10 years). Five of the 13 cell lines were used as controls in
a previous study and were obtained from a Biobank [24].
Eight skin biopsies were taken in connection with ear-




2 skin punch biopsy was taken after anaesthetizing
the mid-forearm under aseptic conditions as described
previously [24]. The tissue was immediately placed in
tubes containing complete culture medium and trans-
ported to the laboratory. From the biopsy was fibroblast
cell lines cultured and stored in a Biobank (-196°C) until
used for the experiments.
Materials
All growth media, antibiotics and fetal bovine serum
(FBS) were obtained from Gibco Invitrogen cell culture
(Sweden).
Tissue culture flasks and multi-well plates were from
Costar Europe Ltd, Costar NY.
14C (U)-L-tyrosine with
specific activity 486 mCi/mmol,
3H(5)-L-tryptophan with
specific activity 30 Ci/mmol and
14C(U)-L- Alanine with
specific activity 110 Ci/mmol were obtained from Larodan
Fine Chemicals AB (Malmö, Sweden). D-Glucose was
obtained from Ambresco (Ohio, USA) and phosphate
buffered saline (PBS) was from the National Veterinary
Institute (SVA) (Uppsala, Sweden). All other chemicals
and amino acids were purchased from Sigma-Aldrich
Sweden AB (Sweden). Scintillation cocktail (Optiphase,
Hisafe 3) and liquid scintillation counter (Winspectral
1414) were from PerkinElmer Life Sciences (USA). Scintil-
lation vials were purchased from Sarstedt AB (Sweden).
Micro-well plates used for protein determination were
purchased from Nunc (Roskilde, Denmark) and readings
were done using Multiscan MS from Labsystems (Hel-
sinki, Finland). All amino acid solutions were made in PBS
and the pH was maintained between 7.35 and 7.40.
Cell culturing
Fibroblast cells were cultured in plastic tissue culture
flasks containing minimal essential medium (MEM) sup-
plemented with 10% FBS, L-glutamine (2 mM/L), peni-
cillin (100 mg/ml), streptomycin (100 mg/ml) and
Amino-Max™. Cells were maintained in a humidified
atmosphere of 5% CO
2 in air at 37°C. Before the mea-
surement of amino acid transport, cells were harvested
when confluent and seeded in 2 cm
2-multi-well plates
and grown to confluence for approximately 5 days. Cell
lines between 4
th and 14
th passages (number of splitting)
were used in the experiments.
Transport assay of amino acids
Amino acid transport was measured using the cluster tray
method for rapid measurement of amino acid flux in
adherent fibroblast cells [25,32,33]. Fibroblasts grown in
multi-well plates were washed twice with PBS and incu-
bated with PBS containing 1% D-glucose for 1 hour at
37°C, to deplete the endogenous amino acid pools. After
removal of the pre-incubation medium, the cells were





alanine and 12 different concentrations (varying between
0.004 and 1.5 mmol/L for tyrosine, 0.005 to 0.5 mmol/L
for tryptophan and 0.02 to 6 mmol/L for alanine) of unla-
belled amino acids. Amino acid transport was terminated
by rapidly washing the cells twice with ice-cold PBS. The
cells were then lysed in 0.2 ml of 0.5 mol/L sodium hydro-
xide (NaOH) for approximately 30 minutes. The radioac-
tivity of the cell lysate was measured by liquid scintillation
counting from a mixture of cell lysate and scintillation
cocktail. The total amino acid uptake was correlated to the
total amount of protein in each well, determined by the
Bradford method [34], using bovine serum albumin as a
standard.
Calculations
The amino acid kinetic parameters Vmaxand Kmwere cal-
culated from the obtained uptake values, corrected for dif-
fusion constant (Kd), by using the Lineweaver-Burke plot
equation [1/V0 =( Km/Vmax[S] + (1/Vmax)] as described
previously [25]. V0 is the initial transport capacity, [S] is
the substrate concentration, Vmax is the maximal transport
capacity (nmol/min/mg protein) and Km, is the affinity
constant (the concentration at half-saturation, μmol/L).
Each experiment was performed in duplicate at the same
time point for all amino acid transport assays and a mean
value was taken for kinetic analysis.
Statistics
All kinetic parameters are presented by descriptive sta-
tistics (mean with standard deviations or median with
Johansson et al. Behavioral and Brain Functions 2011, 7:40
http://www.behavioralandbrainfunctions.com/content/7/1/40
Page 3 of 7range). Assumptions about parametric methods were
fulfilled for Kmof tyrosine, tryptophan and alanine trans-
port, but not for Vmaxof tyrosine, tryptophan and ala-
nine transport (determined using Shapiro-Wilk W test).
Significance of the difference in Kmfor tyrosine, trypto-
phan and alanine transport between children with
ADHD and the comparison group was analysed using the
Student’s unpaired t-test. Significance of the difference in
Vmax for tyrosine, tryptophan and alanine transport
between children with ADHD and the comparison group
was analysed using the Mann Whitney U test.
For all statistical analyses a significant level of 5%
(two-tailed) was accepted. All statistical analyses were
performed using PASW statistics version 18.0 for
Windows.
The study was approved by the Regional Ethics Com-
mittee in Gothenburg, Sweden (Dnr: 218-07). A written
and signed consent was obtained from the parent/s and
their child before performing the studies.
Results
Maximal transport capacity (Vmax) and mean affinity of
binding site (Km) of tyrosine, tryptophan and alanine
transport in children with ADHD and in controls are
presented in Table 1.
Tyrosine
There were no significant differences between the ADHD
group and controls in any of the kinetic parameters
regarding the tyrosine transport (Vmax; p = 0.617, Km;p=
0.645). The median Vmaxfor tyrosine transport was 15.1
(11.5-25.4) nmol/min/mg protein in the ADHD group and
15.5 (7.8-21.5) nmol/min/mg protein in the comparison
group. The mean Kmfor tyrosine transport was 20.0 (6.3)
μmol/L in the ADHD group and 18.8 (5.5) μmol/L in the
comparison group.
Tryptophan
The ADHD group had significantly decreased Vmax (p =
0.039) and Km(p = 0.010) for tryptophan transport in
comparison to controls. The median Vmaxfor tryptophan
transport in the ADHD group was 1.5 (1.1-3.0) nmol/
min/mg protein and for the comparison group 2.0
(1.3-4.7) nmol/min/mg protein. The mean Kmfor trypto-
phan transport in the ADHD group was 13.6 (4.7)
μmol/L and for the comparison group 21.1 (8.2) μmol/L.
Alanine
They ADHD group had a significantly higher Vmaxfor
alanine transport (p = 0.031) than the controls, but the
Km for alanine transport did not differ significantly (p =
0.086). The median Vmaxfor alanine was 42.8 (36.3-64.9)
nmol/min/mg protein in the group of children with
ADHD, while the median Vmaxfor the comparison
group was 32.0 (22.7-63.4) nmol/min/mg protein. The
mean Kmof alanine transport in the ADHD group was
125.7 (41.2) μmol/L and for the comparison group
100.7 (30.1) μmol/L.
Discussion
The main finding in the present study was that the
group with ADHD had a decreased Vmaxof tryptophan
transport and an elevated Vmaxof alanine transport
across the fibroblast cell membranes. A low Vmax
implies that the transport systems have lower capacity
for amino acid uptake, while an increased Vmaxindicates
the opposite. Hence, the children in the ADHD group
had a decreased transport of tryptophan and an elevated
transport of alanine through the cell membrane of fibro-
blasts. Several mechanisms could contribute to the dif-
ferences found between the ADHD group and the
controls; 1) altered expression of transporter proteins
and/or mutation/s in the genes coding for the involved
transporter proteins; 2) general changes in the cell
membrane, such as a disturbed membrane phospholipid
composition (MPC) that could be altering the structure
of the transporter proteins embedded in the membrane,
which in turn might change the functionality of the
transporters; 3) the altered amino acid transport could
be caused by some other molecule(s) affecting the trans-
porter(s) indirectly, e.g. some cytokines are known to
influence amino acid uptake [35-39].
Table 1 Kinetic parameters of tyrosine, tryptophan and alanine transport in fibroblasts from ADHD children





Vmax Tyrosine 15.1 (11.5-25.4) 15.5 (7.8-21.5) 0.617
Tryptophan 1.5 (1.1-3.0) 2.0 (1.3-4.7) 0.039*
Alanine 42.8 (36.3-64.9) 32.0 (22.7-63.4) 0.031*
Km Tyrosine 20.0 (6.3) 18.8 (5.5) 0.645
Tryptophan 13.6 (4.7) 21.1 (8.2) 0.010**
Alanine 125.7 (41.2) 100.7 (30.1) 0.086
The results are presented as median (range) for Vmax values and as mean (standard deviation) for Km values. ADHD, indicates Attention Deficit/Hyperactivity Disorder,
Vmax, indicates maximal transport capacity (nmol/min/mg protein) and Km, indicates affinity of binding sites for a specific amino acid (μmol/l). *Statistically significant
(p ≤ 0.05) **Statistically significant (p ≤ 0.01).
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phan transport, which corresponds to an increased affinity
between the amino acid and the transport protein, indicat-
ing that a lower concentration of extracellular tryptophan
is needed to reach maximal transport capacity. This could
be a compensatory mechanism to the decreased Vmax.
However, there was a negative correlation between the
Vmaxand Kmvalues for tryptophan transport within the
ADHD group (r = -0.70, p = 0.005).
The use of fibroblast cells as a human experimental
model to study amino acid transport across the BBB has
gained support by a number of previous studies [15,
23-29]. Moreover, the amino acid transport systems (i.e.
system L and A) and their isoforms are expressed in
both fibroblasts and at BBB [15,40]. The present find-
ings of altered amino acid transport in fibroblasts from
children with ADHD might therefore also be present at
the BBB.
Implications of an altered tryptophan transport
The decreased transport of tryptophan that was found in
the ADHD group in the present study may imply reduced
levels of serotonin in the CNS that might result in a dis-
turbed serotonergic neurotransmission. A dysfunctional
serotonergic system might secondarily lead to distur-
bances in the catecholaminergic systems as these neuro-
transmitter systems have strong anatomical and
functional interactions [41].
Although the neurotransmitter most clearly implicated
in ADHD is dopamine, there is a considerable amount of
literature associating the serotonergic system with impul-
sivity, i.e. a core symptom in the combined type of ADHD
[ 4 2 ] .T h e r ea r ea l s oe v i d e n c e ss u g g e s t i n gt h a ts e r o t o n i n
may be important in the action of amphetamine to reduce
impulsive behaviour, potentially via its interactions with
the dopaminergic system [43]. The dopamine-serotonin
interaction and evidences for an altered dopaminergic and
serotonergic contribution to ADHD were reviewed com-
prehensively by Oades [9]. The author presented studies
supporting the role of serotonergic activity in impulse
responses and implications as potential target for pharma-
cotherapy. Moreover, adolescents with ADHD and disrup-
tive behaviour were studied by Malmberg et al (2008) with
respect to MAO-A and 5-HTT genes and platelet MAO-B
activity. The importance of further investigations of the
serotonergic system, in addition to the dopaminergic sys-
tem, in individuals with ADHD and disruptive behaviour
disorders was emphasized [44].
If the transport of tryptophan is decreased through the
BBB, as our results indicate, increasing plasma concen-
t r a t i o no ft r y p t o p h a n( e . g .v i a tryptophan supplementa-
tion) might not result in more serotonin production.
This could be one reason for the inconsistent results for
tryptophan supplementation approaches in the treatment
of ADHD [45]. However, some children with ADHD not
responding to single treatment of psychostimulants are
given a combination with selective serotonin reuptake
inhibitors (SSRI) and show beneficial response.
Implications of an altered alanine transport
The physiological relevance of the increased alanine
transport that was found in the ADHD group has not
been explored. However, at physiological plasma con-
centrations there is a competition between amino acids
for transport across the BBB [13-15]. Although alanine
is not involved in the synthesis of neurotransmitters, an
elevated transport of alanine might influence the trans-
port of other amino acids that are of essential impor-
tance for normal brain activity. Moreover, since alanine
is involved in many complex and important metabolic
pathways [46,47], our experiments cannot exclude that
the elevated alanine transport might be related to other
metabolic mechanisms of vital importance for normal
brain activity. An increased transport of alanine has also
been found in children with autism. ADHD and autism
have high co-morbidity [48,49], and the present finding
might imply a shared amino acid transport disturbance.
Implications of an unaltered tyrosine transport
We did not find any significant differences in the transport
of tyrosine between the ADHD group and the control
group. Since tyrosine and tryptophan are considered to be
transported across the BBB in similar fashion (i.e. through
the LAT1 isoform of system L) it is difficult to explain
why the tyrosine transport was not altered, whilst the tryp-
tophan transport was. However, this indicates that it is not
the overall capacity (expression) of system L that is
affected; rather the isolated decrease in the Vmaxfor trypto-
phan could be linked to a more general alteration in
plasma membrane function in ADHD. Altered membrane
composition has been implicated in other psychiatric dis-
orders such as schizophrenia and bipolar disorder [50-53].
Moreover, we measured the total transport of respective
amino acids, i.e. we did not differentiate between the dif-
ferent transport systems and their isoforms.
Possible transporters involved in the altered amino acid
transport found in the ADHD group
In fibroblasts the tryptophan transport is through differ-
ent amino acid transport systems at different substrate
concentrations [22]. In this study we measured the trans-
port of tryptophan at low concentrations (5 μM-500 μM
of tryptophan), i.e. at physiological plasma concentrations
of tryptophan (approximately 50 μM, physiological
plasma levels of tyrosine and alanine are approximately
84 and 250 μM respectively). At this concentration, tryp-
tophan is being transported through the LAT1 isoform of
system L (approximately 80%) and through a high affinity
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or a variant of a known transport system with different
functional properties due to an altered structure or con-
formation of the transporter protein. For example, system
L is known to alter the transport properties due to differ-
ent light-chain subunits [54,55]. The present results
could thus imply that it might be the undefined trypto-
phan transporter that is malfunctioning in ADHD and
not the LAT1 transporter, since the tyrosine transport was
not altered. If this undefined transporter of tryptophan
also exists at the BBB is not known to date. However, tyro-
sine is also transported through the ATA2 isoform of sys-
tem A, which is the major transporter of alanine. The
alanine transport was increased in the ADHD group, indi-
cated by an increased Vmaxbut unchanged Km,a n dt h i s
transport disturbance could be caused by different
mechanisms (see above), such as a higher expression of
the ATA2 transporter protein in the fibroblasts from chil-
dren with ADHD. Hence, if the LAT1 transporter is dis-
turbed, tyrosine could compulsorily be transported
through the ATA2 transporter and therefore the Vmaxof
tyrosine transport will not be affected in the ADHD group.
Limitations
There are certain limitations with the present study. The
patient group was relatively small, i.e. fourteen children
with ADHD. The plasma levels of amino acids were not
determined at the time of the biopsy collection. A further
limitation is that only boys were included. However, our
intention was to include children with a very similar phe-
notype of ADHD according to gender, age, type of ADHD
and etiology. To achieve this we selected only boys (with
the combined type of ADHD) in a rather narrow age span
and for almost all boys there were close relatives/family
members with the same disorder. Moreover, the patients
were on different medications at the time of the biopsy
collection, but it seems rather unlikely that this would
affect the results as the cultivated fibroblasts were seeded
for multiple generations in vitro before being used in the
experiments [16].
Conclusions
In conclusion, children with ADHD may have a
decreased access of tryptophan and an elevated access of
alanine in the brain. The decreased tryptophan availabil-
i t yi nt h eb r a i nm i g h tc a u s ed i s t u r b a n c e si nt h es e r o t o -
nergic neurotransmitter system, which secondarily might
lead to changes in the catecholaminergic system. The
physiological relevance of an increased access of alanine
in the CNS has not been explored. However, this study
was made in vitro, which makes it rather difficult to
translate the results into in vivo situations. A further and
extended exploration concerning the disturbance of
amino acid transport in children with ADHD is thus
necessary. Such exploration should include molecular
investigations, looking for polymorphism in gene loci,
further transport studies including girls with ADHD,
measure the amount of serotonergic receptors in fibro-
blasts and study the effects of different molecules, such
as cytokines, on amino acid uptake.
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